What to do when biologic agents are not working in inflammatory bowel disease patients

Gastroenterology and Hepatology

Volumn 11, Issue 10, 2015, Pages 657-665

  Dalal, Sushila R ^a   Cohen, Russell D ^b  

^a Section of Gastroenterology   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Anti integrin; Anti tumor necrosis factor ; Biologic therapy; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; AZATHIOPRINE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; FC RECEPTOR; GOLIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; VEDOLIZUMAB;

ABDOMINAL PAIN; ANTIBODY PRODUCTION; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL OVERGROWTH; BIOLOGICAL THERAPY; CELIAC DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOSCOPY; FATIGUE; FEVER; HUMAN; IMMUNOMODULATION; MONOTHERAPY; REMISSION; RISK FACTOR; SYMPTOM; ULCERATIVE COLITIS;

EID: 84944412233     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Reddy SS, Brandt LJ. Clostridium difficile infection and inflammatory bowel disease. J Clin Gastroenterol. 2013;47(8):666-671.
2. Ben-Horin S, Margalit M, Bossuyt P, et al; European Crohn's and Colitis Organization (ECCO). Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010;4(2):194-198.
3. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345-351.
4. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478-498, quiz 499.
5. Berg AM, Kelly C P, Farraye FA. Clostridium difficile infection in the inflamma-tory bowel disease patient. Inflamm Bowel Dis. 2013;19(1):194-204.
6. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16(9):1620-1627.
7. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lac-toferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802-819.
8. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6(10):1112-1116.
9. Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013;19(3):621-626.
10. Juillerat P, Wasan SK, Fowler SA, et al. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis. 2013;19(11):2457-2463.
11. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618-627.e3.
12. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(10):1248-1254.
13. Seow H F, Bröer S, Bröer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet. 2004;36(9):1003-1007.
14. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608.
15. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721-1727.
16. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7(9):736-743.
17. Afif W, Loftus EVJ Jr, Faubion WA, et al. Clinical utility of measuring inflix-imab and human anti-chimeric antibody concentrations in patients with inflam-matory bowel disease. Am J Gastroenterol. 2010;105(5):1133-1139.
18. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522-530.e2
19. Brandse J F, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350-355.
20. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297-308.
21. Kevans D, Murthy S, Iacono A, Silverberg MS, Greenberg GR. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142(5):S384-S385.
22. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenter-ology. 2015;148(7):1320-1329.e3.
23. Colombel J-F, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Inf-liximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395.
24. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with inflix-imab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3.
25. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40-47, quiz 48.
26. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444-447.
27. Ma C, Huang V, Fedorak DK, et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther. 2014;40(9):1044-1055.
28. Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin D T. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012;18(1):10-16.
29. Pouw M F, Krieckaert CL, Nurmohamed M T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513-518.
30. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-333, quiz 591.
31. Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut. 2013;62(2):201-208.
32. Colombel J-F, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12(3):423-431.e1.
33. Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators. Certoli-zumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357(3):228-238.
34. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357(3):239-250.
35. Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96-109.
36. Sandborn WJ, Colombel J-F, Enns R, et al; International Efficacy of Natalizumab as Active Crohn's Terapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Terapy (ENACT-2) Trial Group. Natali-zumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353(18):1912-1925.
37. Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedoli-zumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
38. Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group. Vedoli-zumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721.
39. Sands BE, Dubinsky MC, Vermeire S, Sankoh S, Rosario M, Milch C. Effects of increased vedolizumab dosing frequency on clinical remission and response in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2014;20(suppl 1):S1-67.